Following this activity, participants should be able to:

Myeloproliferative Neoplasms and Myelofibrosis: Evolving Management      
• Discuss the clinical evidence supporting the use of JAK2 inhibitors in the management of myelofibrosis.
• Develop an individualized treatment plan for PMF incorporating the currently approved JAK2 inhibitor based on the risk stratification and symptom assessment.

Does Generic Imatinib Change the Treatment Approach in CML?    
• Describe the current standard of care and the impact of generic imatinib for the management of newly diagnosed   patients with CML.
• Identify the challenges associated with the selection of appropriate first-line TKI therapy for the management of patients with CML.

AML: Are We Finally Making Real Progress?      
• Identify the targeted therapies emerging for treatment of AML and discuss how the efficacy of these agents may be dependent on specific subpopulations of AML.

Case Presentations and Panel Discussion (Elderly AML, Slow Responding or Emerging Mutation CML, “Incidental” Identification of a JAK2 Mutant Clone)    
• Describe the clinical challenges in managing patients with elderly AML, slow responding or emerging mutation CML and “incidental” identification of a JAK2 mutant clone.
• Develop an evidence-based approach for the management of patients with elderly AML, slow responding or emerging mutation CML and “incidental” identification of a JAK2 mutant clone.

Case Presentations and Panel Discussion (Nasal NK-T cell, Adult T-cell Leukemia/ Lymphoma, Primary Cutaneous Gamma-delta T-cell Lymphoma)    
• Identify the clinical challenges in managing patients with nasal NK-T cell, ATLL, and primary cutaneous gamma-delta T-cell lymphoma.
• Develop an evidence-based approach for the management of patients with nasal NK-T cell, ATLL, and primary cutaneous gamma-delta T-cell lymphoma.

How I Treat Peripheral T-cell Lymphoma      
• Summarize the current and evolving treatment options for the treatment of PTCL.
• Develop an evidence-based treatment plan integrating novel agents for the management of newly diagnosed and relapsed PTCL.

Supportive Care in the Management of T-cell Lymphomas    
• Review the treatment-related toxicities and the supportive care measures used for their prevention and management in patients with CTCL.
• Identify the risk factors for tumor lysis syndrome (TLS) and develop an effective management strategy for its management in patients with PTCL.

Diffuse Large B-cell Lymphoma: Is Cell of Origin Necessary for Treatment Selection?    
• Describe the molecular heterogeneity of DLBCL and its implications in the management of DLBCL.
• Discuss the evidence from clinical trials on the use of novel therapeutic strategies and how these strategies can be incorporated into current treatment paradigms.

Early-stage Classical Hodgkin Lymphoma (CHL): Can We Eliminate Radiation Therapy for Most Patients?    
• Describe the challenges associated with the management of early stage CHL and the need to develop individualized treatment options.
• Review the evidence from recent clinical trials evaluating the use of chemotherapy alone for early stage CHL.

Shared Decision Making at Key Points in the Management of Hematologic Malignancies    
• Describe key decision points in the management of various hematologic malignancies.
• Discuss the effect on patient outcomes of shared clinician-patient decision making at key decision points.

Case Presentations and Panel Discussion (Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma with Renal Failure)
• Identify the clinical challenges in managing patients with smoldering myeloma, MGUS and multiple myeloma with renal failure.
• Develop an evidence-based approach for the management of patients with smoldering myeloma, MGUS and multiple myeloma with renal failure.

Multiple Myeloma: Diagnosis and Primary Treatment    
• Apply the updated criteria for diagnosis of multiple myeloma.
• Understand the data supporting newer treatment options in patients with newly diagnosed multiple myeloma.

How to Integrate the New Drugs into Therapy of Myeloma    
• Incorporate the new regimens in the clinical management of patients with multiple myeloma.

Getting Patients through Therapy: Supportive Care in Multiple Myeloma    
• Identify the classic clinical presentation and symptoms of multiple myeloma.
• Identify nursing interventions to provide supportive care for patients with multiple myeloma.
• Outline supportive care strategies for patients with multiple myeloma.

ALL: New Options for Relapsed Disease    
• Review the clinical data and discuss ongoing trials that are evaluating immunotherapy in the setting of relapsed or refractory ALL.

Debate—Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy    
• Discuss the evidence from clinical trials supporting the use of chemoimmunotherapy and TKI therapy for newly diagnosed patients with CLL.
• Identify patients with CLL who could be candidates for first-line therapy with TKIs and develop an individualized treatment plan for patients with newly diagnosed CLL.